ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v21i1.2657ppharm-2422Research ArticleИНФОРМАЦИЯ СОЮЗА ПЕДИАТРОВ РОССИИFROM THE UNION OF PEDIATRICIANS OF RUSSIAРезолюция по итогам экспертного советаRESOLUTION ON THE RESULTS OF THE EXPERT COUNCILРедакционнаястатьяEditorialArticle2024250220242116669Copyright © Редакционная с., 20242024Редакционная с.Editorial a.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2422

2 декабря 2023 г. в Москве при поддержке компании «Нанолек» состоялся совет экспертов на тему «Современный подход к диагностике и терапии нейропатической формы мукополисахаридоза II типа»

.

ReferencesMartin R, Beck M, Eng C, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008;121(2):e377–e386. https://doi.org/10.1542/peds.2007-135Martin R, Beck M, Eng C, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008;121(2):e377–e386. https://doi.org/10.1542/peds.2007-135Stapleton M, Kubaski F, Mason RW, et al. Presentation and treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome). Expert Opin Orphan Drugs. 2017;5(4):295–307. https://doi.org/10.1080/21678707.2017.1296761Stapleton M, Kubaski F, Mason RW, et al. Presentation and treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome). Expert Opin Orphan Drugs. 2017;5(4):295–307. https://doi.org/10.1080/21678707.2017.1296761Носко А.С., Зыков В.П., Новикова Е.Б. Алгоритм дифференциальной диагностики неврологических нарушений у пациентов с синдромом Хантера // Поликлиника. — 2022. — № 1. — С. 20–23. [Nosko AS, Zykov VP, Novikova EB. Algorithm of differential diagnosis of neurological disorders in patients with Hunter syndrome. Poliklinika. 2022;(1):20–23. (In Russ).]Носко А.С., Зыков В.П., Новикова Е.Б. Алгоритм дифференциальной диагностики неврологических нарушений у пациентов с синдромом Хантера // Поликлиника. — 2022. — № 1. — С. 20–23. [Nosko AS, Zykov VP, Novikova EB. Algorithm of differential diagnosis of neurological disorders in patients with Hunter syndrome. Poliklinika. 2022;(1):20–23. (In Russ).]Holt J, Poe MD, Escolar ML. Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II. J Pediatr. 2011;159(2):320–326.e2. https://doi.org/10.1016/j.jpeds.2011.03.019Holt J, Poe MD, Escolar ML. Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II. J Pediatr. 2011;159(2):320–326.e2. https://doi.org/10.1016/j.jpeds.2011.03.019Shapiro EG, Jones SA, Escolar ML. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations — Neurological signs and symptoms. Mol Genet Metab. 2017;122S:1–7. https://doi.org/10.1016/j.ymgme.2017.08.009Shapiro EG, Jones SA, Escolar ML. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations — Neurological signs and symptoms. Mol Genet Metab. 2017;122S:1–7. https://doi.org/10.1016/j.ymgme.2017.08.009Vollebregt AAM, Hoogeveen-Westerveld M, Kroos MA, et al. Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype. Dev Med Child Neurol. 2017;59(10):1063–1070. https://doi.org/10.1111/dmcn.13467Vollebregt AAM, Hoogeveen-Westerveld M, Kroos MA, et al. Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype. Dev Med Child Neurol. 2017;59(10):1063–1070. https://doi.org/10.1111/dmcn.13467Kim C, Seo J, Chung Y, et al. Comparative study of idursulfase beta and idursulfase in vitro and in vivo. J Hum Genet. 2017;62(2): 167–174. doi: 10.1038/jhg.2016.133Kim C, Seo J, Chung Y, et al. Comparative study of idursulfase beta and idursulfase in vitro and in vivo. J Hum Genet. 2017;62(2): 167–174. doi: 10.1038/jhg.2016.133Calias P, Papisov M, Pan J, et al. CNS penetration of intrathecallumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS ONE. 2012;7(1):e30341. https://doi.org/10.1371/journal.pone.0030341Calias P, Papisov M, Pan J, et al. CNS penetration of intrathecallumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS ONE. 2012;7(1):e30341. https://doi.org/10.1371/journal.pone.0030341Seo JH, Kosuga M, Hamazaki T, et al. Intracerebroventricular enzyme replacement therapy inpatientswithneuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1/2 study. Mol Genet Metab. 2023;140(4):107709. https://doi.org/10.1016/j.ymgme.2023.107709Seo JH, Kosuga M, Hamazaki T, et al. Intracerebroventricular enzyme replacement therapy inpatientswithneuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1/2 study. Mol Genet Metab. 2023;140(4):107709. https://doi.org/10.1016/j.ymgme.2023.107709Seo JH, Kosuga M, Hamazaki T, et al. Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II. Mol Ther Methods Clin Dev. 2021;21:67–75. https://doi.org/10.1016/j.omtm.2021.02.018Seo JH, Kosuga M, Hamazaki T, et al. Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II. Mol Ther Methods Clin Dev. 2021;21:67–75. https://doi.org/10.1016/j.omtm.2021.02.018Озеров С.С., Мельников А.В., Самарин А.Е. и др. Резервуар Оммайя для проведения интравентрикулярной химиотерапии у детей с нейроонкологическими и онкогематологическими заболеваниями: история создания, техника постанов ки и опыт Федерального научно-клинического центра детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. — 2015. — Т. 14. — № 4. — С. 5–9. — https://doi.org/10.24287/1726-17082015-14-4-5-9Ozerov SS, Melnikov AV, Samarin AE, et al. Ommaya reservoir for intraventricular chemotherapy of children with neuro-oncological and oncohematological diseases: Design history, implantation technology, and experience gained at the Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev. Pediatric Hematology/Oncology and Immunopathology. 2015;14(4):5–9. (In Russ). doi: https://doi.org/10.24287/1726-1708-2015-144-5-9

The authors declare that there are no conflicts of interest present.